Skadden-Led Chinese Biotech Launches $100M IPO In US
Skadden-advised Chinese biotechnology company I-Mab set a price range Friday for a potential $100 million U.S. initial public offering in what could be the first IPO of 2020....To view the full article, register now.
Already a subscriber? Click here to view full article